March 27th 2023
In an interview, Edwin Choy, MD, discussed the treatment landscape of GIST and recent changes to NCCN guidelines.
February 3rd 2023
Ripretinib Shows Better Efficacy Than Sunitinib in Imatinib-Pretreated Patients With KIT-Mutated GISTJanuary 5th 2023
INTRIGUE study results show that patients with gastrointestinal stromal tumor who harbor certain KIT mutations have significantly improved responses and survival with ripretinib treatment.
Targeted Therapy Is Considered a Necessity for Metastatic GISTMarch 23rd 2022
Targeted therapy with tyrosine kinase inhibitors is necessary after surgery for patients with metastatic gastrointestinal stromal tumors with residual disease requiring resection to prevent disease recurrence.
Ripretinib Maintains PFS Benefit and Shows Favorable OS in Advanced GISTNovember 11th 2021
Full results from the phase 3 INVICTUS trial show stable progression-free survival advantage and improved overall survival with ripretinib in patients with an advanced gastrointestinal stromal tumor.
Pimitespib Shows Significant PFS Improvement in Advanced Refractory GISTJune 8th 2021
Pimitespib, a heat shock protein 90 inhibitor doubled the progression-free survival and prolonged the overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib, according to results from the phase 3 CHAPTER-GIST-301 trial.
Increased Dose of Ripretinib Improves Survival in Heavily Pretreated Advanced GISTJune 4th 2021
Patients with advanced gastrointestinal stromal tumor after receiving fourth-line therapy had extended progression-free survival when given an intra-patient dose escalation of ripretinib to 150 mg twice a day following progression.
More Benefit Observed With Avapritinib Than Other TKIs in Mutated GISTMay 21st 2021
A retrospective analysis showed there were more durable survival outcomes with avapritinib versus other tyrosine kinase inhibitors in adult patients with gastrointestinal stromal tumors and a platelet-derived growth factor receptor A D842V mutation
Precision Medicine Stakes Claim in the Gastrointestinal Stromal Tumors LandscapeMarch 9th 2021
In an interview with Targeted Oncology, Margaret von Mehren, MD, reviews the recent advancements in the GIST treatment landscape. She also explains what’s needed to move the needle further in the future.
Adjuvant Imatinib Confirmed Beneficial for RFS in High-Risk Gastrointestinal Stromal TumorsFebruary 20th 2021
Adjuvant imatinib has demonstrated significant improvement in relapse-free survival over a 2-year period and a mild trend toward long-term improvement in failure-free survival as treatment of patients with high-risk gastrointestinal stromal tumors, according to 9.1-year follow-up results from a randomized phase 3 study.
FDA-Approved Advanced GIST Therapy Can Elicit Durable Responses With Tolerable SafetyFebruary 20th 2021
In patients with gastrointestinal stromal tumors who have received 3 or more prior therapies, there remain unmet needs to overcome resistance to the standard-of-care, imatinib, a tyrosine kinase inhibitor, and prolong the 6.3-month+ progression-free survival achieved with the FDA-approved TKI ripretinib.
Invasive GIST Originating in the Stomach/Small Intestine Is More Common in Men, Study ShowsFebruary 19th 2021
Men appear to be more likely than women to have invasive gastrointestinal stromal tumors originating in the stomach and small intestines. For treatment, an expert says that combined surgery and systemic therapy demonstrates the best outcomes.
Continued PFS, OS Benefit Seen With Ripretinib in Advanced GISTSeptember 19th 2020
For patients with advanced gastrointestinal stromal tumors, there was continued clinically meaningful benefit with the novel broad-spectrum KIT and PDGFRα inhibitor ripretinib in the fourth line or later, according to updated data from the randomized phase 3 INVICTUS trial presented at the 2020 ESMO Virtual Congress.
Binimetinib Added to Standard of Care Elicits Responses in Advanced GISTJuly 20th 2020
In an interview with Targeted Oncology, Ping Chi, MD medical oncologist, Geoffrey Beene Junior Faculty chair, Memorial Sloan Kettering Cancer Center, discussed the phase 2 study of binimetinib in combination with imatinib in patients with untreated advanced GIST.